Identification of 7 Proteins in Sera of RA Patients with Potential to Predict ETA/MTX Treatment Response.

ABSTRACT:

Objective

The recent growth of innovating biologics has opened fascinating avenues for the management of patients. In rheumatoid arthritis, many biologics are currently available, the choice of which being mostly determined empirically. Importantly, a given biologic may not be active in a fraction of patients and may even provoke side effects. Here, we conducted a comparative proteomics study in attempt to identify a predictive theranostic signature of non-response in patients with rheumatoid arthritis treated by etanercept/methotrexate combination.

Methods

A serum sample was collected prior to treatment exposure from a cohort of 22 patients with active RA. A proteomic "label free" approach was then designed to quantitate protein biomarkers using mass spectrometry. To verify

SUBMITTER: Obry A 

PROVIDER: S-EPMC4568449 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature